BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 12, 2015
 |  BioCentury  |  Finance

ONCE upon a time

Parsing Spark's rollercoaster week on positive Phase III gene therapy data

Last week's stock move by Spark Therapeutics Inc. (NASDAQ:ONCE) has its investors scratching their heads, as positive Phase III data did little to reignite interest in the ophthalmic gene therapy play. Instead, the stock remains more than 40% below its 52-week high of $79.50.

Spark jumped 21% to $53.02 last Monday when its SPK-RPE65 met the primary endpoint in a trial to treat RPE65-mediated inherited retinal dystrophies. But the company gave back those gains over Tuesday and Wednesday, then drifted up on Thursday and Friday to end the week at $49.30, up $5.37 (12%).

Biotech indices including the BioCentury 100 slipped 2% on the week,...

Read the full 530 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >